Skip to content

Author: Orum Therapeutics

Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate

August 22, 2026

All content ©2025 Tork Media
All Rights Reserved. For more information on this site, please read our Privacy Policy, Terms of Service, Cookie Policy, and Ad Choices.